EVEREST STUDY: Efficacy and Safety of Verteporfin Photodynamic Therapy in Combination with Ranibizumab or Alone Versus Ranibizumab Monotherapy in Patients with Symptomatic Macular Polypoidal Choroidal Vasculopathy
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To assess the effects of verteporfin photodynamic therapy (PDT) combined with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Methods: In this multicenter, double-masked, primarily indocyanine green angiography–guided trial, 61 Asian patients were randomized to verteporfin PDT (standard fluence), ranibizumab 0.5 mg, or the combination. Patients were administered with verteporfin PDT/placebo and initiated with three consecutive monthly ranibizumab/sham injections starting Day 1, and re-treated (Months 3–5) as per predefined criteria. The primary endpoint was the proportion of patients with indocyanine green angiography–assessed complete regression of polyps at Month 6. Secondary endpoints included mean change in best-corrected visual acuity at Month 6 and safety. Results: At Month 6, verteporfin combined with ranibizumab or alone was superior to ranibizumab monotherapy in achieving complete polyp regression (77.8% and 71.4% vs. 28.6%; P < 0.01); mean change ± standard deviation in best-corrected visual acuity (letters) was 10.9 ± 10.9 (verteporfin PDT + ranibizumab), 7.5 ± 10.6 (verteporfin PDT), and 9.2 ± 12.4 (ranibizumab). There were no new safety findings with either drug used alone or in combination. Conclusion: Verteporfin PDT combined with ranibizumab 0.5 mg or alone was superior to ranibizumab monotherapy in achieving complete regression of polyps in this 6-month study in patients with symptomatic macular polypoidal choroidal vasculopathy. All treatments were well tolerated over 6 months. EVEREST, the first, multicenter, double-masked, primarily indocyanine green angiography–guided randomized controlled trial for symptomatic macular polypoidal choroidal vasculopathy, demonstrated superiority of verteporfin photodynamic therapy combined with ranibizumab or alone over ranibizumab monotherapy in achieving complete regression of polyps at Month 6. Best-corrected visual acuity improved in all treatment arms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the United Kingdom, ICGA is not available in all units and is usually reserved for cases presenting with clinical features suspicious of polypoidal choroidopathy (IPCV) or retinal angiomatous proliferation (RAP) or when response to anti-VEGF therapy is suboptimal.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“Some lesion types are thought to be less responsive than others to anti-VEGF therapy, for example, IPCV.”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“The EVEREST study suggested that combination therapy of IPCV with photodynamic therapy (PDT) and ranibizumab led to a better outcome than monotherapy with ranibizumab.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
In the citing paper
“However, an expanding or increased elevation in PED indicates activity that merits evaluation and treatment.11,12”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [11]
Citations
Cites
Chung, S. E., Kang, S. W., Lee, J. H., & Kim, Y. T. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.09.012 · Cited by 580
Polypoidal Choroidal Vasculopathy: Incidence, Demographic Features, and Clinical Characteristics
Sho, K. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.10.1392 · Cited by 439 · cited 1×
“Moreover, the incidence of sub-RPE hemorrhage or subretinal hemorrhage in patients with PCV is high (30%–64%).(3,9) In a study of the natural history of patients with PCV, Uyama et al(6) reported that half of the study eyes had hemorrhagic episodes, recurrent leakage, or severe RPE atrophy after a long follow-up perio…”
BackgroundThe Expanding Clinical Spectrum of Idiopathic Polypoidal Choroidal Vasculopathy
Yannuzzi, L. A. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100150480005 · Cited by 436 · cited 3×
“It may be associated with a branching vascular network (BVN) and clinically visible orange-red subretinal nodule(s).(1) Polypoidal choroidal vasculopathy is prevalent in 10% to 54% of the Asian patients and in 8% to 12% of white patients with presumed exudative age-related macular degeneration (AMD).”
BackgroundPolypoidal choroidal vasculopathy: natural history
Uyama, M., Wada, M., Nagai, Y., Matsubara, T., Matsunaga, H., Fukushima, I., Takahashi, K., & Matsumura, M. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01404-6 · Cited by 402 · cited 3×
“In PCV, the polypoidal lesions originate from the inner choroidal vasculature and can progress beneath the RPE.(1,6,7) The presence of orange-red nodule–like structures beneath the RPE associated with an adjacent serous pigment epithelial detachment or overlying neurosensory detachment, subretinal hemorrhage, and lipi…”
BackgroundTong, J.-P., Chan, W.-M., Liu, D. T. L., Lai, T. Y. Y., Choy, K.-W., Pang, C.-P., & Lam, D. S. C. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.10.012 · Cited by 385 · cited 1×
“The increased expression of VEGF in the aqueous humor of eyes with PCV provides a biologic rationale for treatment with anti-VEGF agents.(19) Limited data from case series with bevacizumab monotherapy have shown that treatment may reduce leakage associated with PCV but is ineffective for complete regression of the pol…”
BackgroundSelf-citationPhotodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy
Chan, W.-M., Lam, D. S. C., Lai, T. Y. Y., Liu, D. T. L., Li, K. K. W., Yao, Y., & Wong, T.-H. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2003.12.056 · Cited by 283
Self-citation(2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(03)00223-x · Cited by 274 · cited 1×
“For CNV secondary to AMD, the Verteporfin In Photodynamic Therapy and the Treatment of AMD with Photodynamic Therapy study has demonstrated that there was gradual visual deterioration or no visual improvement with high re-treatment rate at 6 months for treated patients after verteporfin PDT administration.(25) This tr…”
ResultEfficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy
Gomi, F., Sawa, M., Sakaguchi, H., Tsujikawa, M., Oshima, Y., Kamei, M., & Tano, Y. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.122283 · Cited by 242 · cited 1×
“These findings are consistent with those reported earlier with other anti-VEGF therapies.(20,21)”
ResultGomi, F., Ohji, M., Sayanagi, K., Sawa, M., Sakaguchi, H., Oshima, Y., Ikuno, Y., & Tano, Y. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.02.031 · Cited by 239
The origins of polypoidal choroidal vasculopathy
Yuzawa, M. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2004.049296 · Cited by 198 · cited 4×
“Use of dynamic confocal scanning laser ophthalmoscope–ICGA may assist in further elucidating the BVN, from which these focal evaginating nodules arise, enabling clearer definition and differentiation from exudative AMD because of CNV.(7) Based on ICGA findings, PCV is defined as the presence of single or multiple foca…”
BackgroundInfluential
Cited by
Items 401–500 of 586
Age-Related Macular Degeneration (AMD): Non-neovascular and Neovascular AMD
Chaikitmongkol, V., Bressler, S. B., & Bressler, N. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-42634-7_111 · Cited by 6
Liu, S., & Chhabra, R. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05724-4 · Cited by 4
“Large clinical trials revealed the superiority of intravitreal injections of anti-VEGFs in maintaining vision over PDT monotherapy [12, 13], whilst PDT was more effective in regressing polyps [9] than anti-VEGF monotherapy.”
BackgroundSiedlecki, J., Klaas, J. E., Keidel, L. F., Asani, B., Schiefelbein, J. B., Knebel, D., Luft, N., Priglinger, S. G., & Schworm, B. (2023) · Eye · doi:10.1038/s41433-023-02529-5 · Cited by 4
Farooq, A., Frazier, H., Marcus, W. B., Fechter, C., Singh, H., & Marcus, D. M. (2017) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20161219-05 · Cited by 4
Weng, H.-Y., Huang, T., Chang, P.-Y., & Wang, J.-K. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-019-0310-1 · Cited by 4
Chehab, H. E., Kodjikian, L., Lagenaite, C., Agard, É., Bats, F. D., Mathis, T., & Dot, C. (2019) · European Journal of Ophthalmology · doi:10.1177/1120672119874674 · Cited by 4
“950 European Journal of Ophthalmology 30(5)”
InfluentialAsano-Shimizu, K., Asano, S., Murata, H., Azuma, K., Nomura, Y., Inoue, T., Ogawa, A., Asaoka, R., & Obata, R. (2020) · International Ophthalmology · doi:10.1007/s10792-020-01299-3 · Cited by 4
“PCV was diagnosed based on previous reports [10, 13, 28].”
MethodResultMallikarjun, K. S., Narayanan, R., Raman, R., Mohamed, A., Shanmugam, M. P., Apte, R. S., & Padhy, S. K. (2021) · International Ophthalmology · doi:10.1007/s10792-021-02113-4 · Cited by 5
Okada, A. A., Yamamoto, Y., Sugitani, Kunita, Rii, T., & Yokota (2013) · Clinical ophthalmology · doi:10.2147/opth.s42189 · Cited by 4
Salvo, G. D., Vaz-Pereira, S., Sehmi, K. S., Andrews, R. M., & Sagoo, M. S. (2015) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20151027-15 · Cited by 4
Lee, D., Jeong, S., Moon, J., Lee, J., & Sagong, M. (2016) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2016.57.10.1577 · Cited by 4
Hsia, Y., Chan, L.-W., Yang, C., Yang, C., & Hsieh, Y. (2019) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2019.06.004 · Cited by 4
Pedanova, E. K., & Дога, А. В. (2019) · Ophthalmology in Russia · doi:10.18008/1816-5095-2019-2-151-158 · Cited by 4
“Так, при моно‐ терапии Ранибизумабом полное закрытие полипов было отмечено лишь в 28,6 % случаев, тогда как в группе ФДТ оно достигало 71,4 % (p < 0,01) [37].”
Yoneda, A., Wakiyama, H., Kurihara, J., & Kitaoka, T. (2019) · European Journal of Ophthalmology · doi:10.1177/1120672119871886 · Cited by 4
Karaçorlu, M., Hocaoğlu, M., Arf, S., Ersöz, M. G., & Muslubaş, I. S. (2019) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.galenos.2019.26235 · Cited by 5
Histopathology of Age-Related Macular Degeneration and Implications for Pathogenesis and Therapy
Chee, R.-I., Mahrous, A., Koenig, L., Mandel, L. S., Yazdanie, F., Chan, C., & Patel, M. M. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-66014-7_3 · Cited by 5
Age-Related Macular Degeneration (AMD): Non-neovascular and Neovascular AMD
Chaikitmongkol, V., Bressler, S. B., & Bressler, N. M. (2020) · Springer eBooks · doi:10.1007/978-3-319-90495-5_111-1 · Cited by 4
Outcomes of polypoidal choroidal vasculopathy treated with ranibizumab monotherapy
Tan, C. S., Ngo, W. K., Lim, L. W., Cheong, K. X., & Lim, T. H. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304046 · Cited by 5
Self-citationPolypoidal Choroidal Vasculopathy: From Clinicopathological and Molecular Perspectives
Zhang, C., Zhang, W., Wang, T., Wen, L., & Zhang, J. (2025) · Ophthalmic Research · doi:10.1159/000548709 · Cited by 5
“…closure rates are approximately 28.6% within 6 months (EVEREST I study) and 44.7% within 12 months (EVEREST II study) for ranibizumab (3 + PRN) [25, 26], 38.9% within 12 months (PLANET study) for aflibercept (2 mg q8w) [27], and 48.7% within 4 months of loading doses for faricimab in…”
InfluentialLin, T.-H., Lin, H., & Tseng, P.-C. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.12.006 · Cited by 3
Ling, L., Ma, J., Duan, P., Liu, Y., & Yin, Z. Q. (2015) · Europe PMC (PubMed Central) · Cited by 3
Simonett, J. M., Chan, E. W., Chou, J. C., Skondra, D., Colon, D., Chee, C., Gopal, L., & Fawzi, A. A. (2017) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20170130-06 · Cited by 3
Choo, H. G., Lee, J. H., Oh, H. S., Kim, S. H., You, Y. S., & Kwon, O. W. (2021) · BMC Ophthalmology · doi:10.1186/s12886-021-01829-2 · Cited by 3
Wang, W.-Y., Yang, C., Chen, T., Hsieh, Y., Ho, T., Yang, C., Liu, F.-Y., & Lai, T. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05583-z · Cited by 3
Self-citationIMAGING AND CLINICAL FEATURES OF PULSATILE POLYPOIDAL CHOROIDAL VASCULOPATHY
Choi, K.-E., Lee, Y. J., & Bae, S. H. (2024) · Retina · doi:10.1097/iae.0000000000004057 · Cited by 3
Two-year outcomes of intravitreal conbercept therapy for polypoidal choroidal vasculopathy
Liu, Y., Guo, J., Tang, W., Xu, G., & Liu, W. (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03687-0 · Cited by 3
“…complete regression: no polyp observed on the imaging; (2) partial regression: ≥ 10% decrease in the polyp area compared with the baseline; (3) no change: < 10% increase in the polyp area compared with the baseline; and (4) increase: ≥ 10% increase in the polyp area compared with the baseline [12].”
ResultPhotosensitizer formulations in photodynamic therapy of age-related macular degeneration
Beirão, S., Pereira, P. M. R., Fernandes, R., & Tomé, J. P. C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117105 · Cited by 6
Honda, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041240 · Cited by 6
“The EVEREST study [24], a randomized, double-blind, prospective comparative study involving 61 patients with PCV conducted in Asia at the same time as the abovementioned study, evaluated the outcomes of patients treated with ranibizumab alone, PDT alone, and a combination of ranibizumab + PDT.”
Eriş, E., & Vural, E. (2018) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2018.10.007 · Cited by 3
Wang, Y., Chen, Z., Yu, W., & Chen, Y. (2021) · BMC Ophthalmology · doi:10.1186/s12886-021-02080-5 · Cited by 3
“According to the EVEREST criteria, focal hyperfluorescent lesions appearing before 6 min on ICGA is a necessary criterion for PCV diagnosis [7].”
MethodChang, Y. S., Kim, J. H., Kim, J. W., Lee, T. G., & Kim, C. G. (2016) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2016.30.4.272 · Cited by 3
“PDT is considered to have higher efficacy than anti-VEGF therapy in PCV, particularly in regressing polyps [24], although the issue remains controversial [1].”
BackgroundSen, P., Saurabh, K., Bhende, M. P., & Sharma, T. (2016) · Oman Journal of Ophthalmology · doi:10.4103/0974-620x.192263 · Cited by 4
“[9] In some cases even if subretinal fluid (SRF) and blood involve the fovea, ICGA may reveal a substantial proportion of polyps to be extrafoveal and amenable to focal argon laser photocoagulation once the surrounding SRF and hemorrhage subsides following intravitreal anti‑VEGF injection.”
Sen, P., Bhende, M. P., Sachidanandam, R., Bansal, N., & Sharma, T. (2016) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.198856 · Cited by 3
Photodynamic therapy for polypoidal choroidal vasculopathy secondary to choroidal nevus
Wong, J., Lai, X. J., Sarafian, R. Y., Wong, H. S., & Smith, J. B. (2017) · International Medical Case Reports Journal · doi:10.2147/imcrj.s107648 · Cited by 3
Mohamad, N. A., Ramachandran, V., Ismail, P., Isa, H. M., Chan, Y. M., Ngah, N. F., Bakri, N. M., Ching, S. M., Hoo, F. K., & Sulaiman, W. A. W. (2017) · International Journal of Ophthalmology · doi:10.18240/ijo.2017.12.16 · Cited by 3
Polypoidal Choroidal Vasculopathy Associated with Optic Disc Coloboma
Nakano, Y., Miki, A., Honda, S., & Nakamura, M. (2018) · Case Reports in Ophthalmology · doi:10.1159/000485966 · Cited by 3
Ghoshal, R., Sharanjeet-Kaur, S., Fadzil, N. M., Ghosh, S., Ngah, N. F., & Aziz, R. A. B. A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18052581 · Cited by 3
“Thus, a combination therapy of anti-VEGF and PDT is considered as superior in achieving better morphological and visual outcome in PCV eyes [13].”
BackgroundResultInfluentialMonés, J., Badal, J. M., & Biarnés, M. (2015) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000000174 · Cited by 3
Tan, C. S., Ngo, W. K., & Lim, L. W. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.07.005 · Cited by 3
Jezani, S. N., & Bastion, M.-L. C. (2025) · Medicine · doi:10.1097/md.0000000000042666 · Cited by 4
“[75] Nevertheless, 71.4% of PCV cases do not respond well or fully to anti-VEGF.”
InfluentialImaging techniques for the detection of choroidal neovascularization
Mi, Z., & Paulus, Y. M. (2025) · Experimental Eye Research · doi:10.1016/j.exer.2025.110522 · Cited by 2
OCT and OCTA quantitative metrics for polypoidal choroidal vasculopathy
Zeng, Y. J., Qiu, B., Chen, X., & Zhang, X. (2025) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2024-002132 · Cited by 2
Fukuda, Y., Sakurada, Y., Kotoda, Y., Kimura, M., & Kashiwagi, K. (2025) · Pharmaceuticals · doi:10.3390/ph18121811 · Cited by 3
“…combination therapy involving PDT and ranibizumab is superior to ranibizumab monotherapy in terms of complete regression of polypoidal lesions, with no significant differences in BCVA improvement (PDT with ranibizumab group: 10.9 ± 10.9 letters vs. ranibizumab monotherapy: 9.2 ± 12.4 letters) [38].”
InfluentialComparing Ranibizumab and Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy
Song, M., Cho, A. R., Kim, Y. J., Kim, J.-G., Yoon, Y. H., & Lee, J. Y. (2018) · Journal of Retina · doi:10.21561/jor.2018.3.1.49 · Cited by 2
“Photodynamic therapy (PDT) with verteporfin and PDT in combination with anti-vascular endothelial growth factor (VEGF) drugs is safe and effective for treating PCV [8-11].”
BackgroundMethodNam, K. T., Yun, C., Lee, Y. J., Choi, M., Kang, D., & Oh, J. (2024) · Current Eye Research · doi:10.1080/02713683.2024.2323506 · Cited by 2
Advanced age-related macular degeneration and risk factors in eyes with pachydrusen
Nam, S. W., Noh, H., Yoon, J. M., & Ham, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-56404-8 · Cited by 3
“PCV diagnosis was made using the EVEREST study criteria, which is focusing on the presence of focal hyperfluorescent lesions (aneurysms/polyps) appearing on ICGA before minute 6, associated with a branching vascular network/type 1 MNV 21 .”
MethodWeng, H.-Y., Chen, F., Wang, L.-U., Huang, T., Ho, W., Chang, P.-Y., Hsu, Y.-R., Chen, Y.-J., & Wang, J.-K. (2024) · Medicina · doi:10.3390/medicina60081311 · Cited by 2
“The EVEREST study found that the complete polyp regression rates in combination therapy of PDT and intravitreal ranibizumab (IVR) or in PDT alone were higher than in IVR monotherapy [10].”
BackgroundResultGergely, R., Ecsedy, M., Kovács, I., Papp, A., Resch, M., Récsán, Z., Szabó, A., & Nagy, Z. Z. (2021) · Orvosi Hetilap · doi:10.1556/650.2021.32062 · Cited by 2
Dat, D. T., Hien, N., Nguyen, Q. N., Tùng, M. Q., Tam, H., & Hung, B. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164678 · Cited by 4
“There were no safety concerns with any of the treatment regimens [72].”
BackgroundPolypoidal Choroidal Vasculopathy in patients diagnosed with age-related macular degeneration
Tan, C. S., Lim, L. W., Ngo, W. K., & Lim, T. H. (2013) · Acta Ophthalmologica · doi:10.1111/aos.12214 · Cited by 2
“We would like to highlight the importance of both these features, which are among the six diagnostic criteria for PCV which was used in the EVEREST study (Lim et al. 2010; Koh et al. 2012).”
BackgroundMethodResultSelf-citationResponse-based individualized medicine for neovascular age-related macular degeneration
Yasukawa, T. (2015) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.1019473 · Cited by 3
“Some of these cases would rather be treated by the photodynamic therapy (PDT) [22].”
BackgroundMethodInfluentialEplerenone in the Treatment of Polypoidal Choroidal Vasculopathy
Kapoor, K., & Wagner, A. L. (2015) · Case Reports in Ophthalmology · doi:10.1159/000442661 · Cited by 2
Paradigm of Susceptibility Genes in AMD and PCV
Riaz, M., & Baird, P. N. (2017) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-4-431-56511-6_14 · Cited by 2
Medina-Baena, M., Huertos-Carrillo, M. J., Rodríguez, L., García-Pulido, J. I., Cornejo-Castillo, C., & Calandria-Amigueti, J. M. (2018) · Case Reports in Ophthalmology · doi:10.1159/000487227 · Cited by 2
Safety of photodynamic therapy involving optic nerve head
Manayath, G. J., Verghese, S., Jain, N., Ranjan, R., & Narendran, V. (2020) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1081_19 · Cited by 2
“PDT in combination with anti-VEGF is recommended as initial therapy for subfoveal or juxtafoveal PCV, while anti-VEGF monotherapy is used as alternate treatment option where PDT is considered risky or unaffordable.[2] For peripapillary PCV, focal laser or anti-VEGF is usually preferred, as optic nerve head (ONH) safet…”
BackgroundPolypoidal Choroidal Vasculopathy
Chawla, H., & Vohra, V. (2021) · StatPearls · Cited by 2
Guo, J., Qiu, X., Tang, W., Xu, G., Moyers, M. F., Ren, W., Xing, Y., Gao, J. M., Sun, J., Lu, J. J., et al. (2021) · Ophthalmology and Therapy · doi:10.1007/s40123-021-00409-3 · Cited by 2
“Patients with persistent fluid may also develop resistance to the anti-VEGF therapy, including drug tolerance, tachyphylaxis, and changes in the neovascular architecture, which can diminish the therapeutic effects of the drug [3, 4, 20].”
BackgroundInfluentialDégénérescence maculaire liée à l’âge. État des lieux 2015
Haddad, W. M. (2015) · Revue Francophone d Orthoptie · doi:10.1016/j.rfo.2015.04.014 · Cited by 3
Kumar, S., & Fu, Y. (2021) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-981-15-9184-6_5 · Cited by 1
Erden, M., Önder, F., & Ayrancıoğlu, B. N. (2024) · Medical Science and Discovery · doi:10.36472/msd.v11i1.1002 · Cited by 1
“In addition to choroidal hemangiomas and choroidal retinopathies, it has been used for polypoidal choroidal vasculopathy and peripapillary choroidal neovascularizations (7).”
BackgroundMethodKim, J. H., Park, S. M., Kim, C. G., & Kim, C. G. (2024) · Scientific Reports · doi:10.1038/s41598-024-72670-y · Cited by 1
Rizzo, C., Savastano, M. C., Kilian, R. A., & Rizzo, S. (2025) · European Journal of Ophthalmology · doi:10.1177/11206721241310629 · Cited by 1
Kuo, P.-C., Hsu, S., Huang, Y.-H., Chang, C., Chang, Y.-S., Hung, J., Lai, C., & Lee, Y.-K. (2025) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2025.104531 · Cited by 1
Exploring Clinical Features of Polypoidal Choroidal Vasculopathy in Black Patients
Lazrak, A., Bonnafous, M., Jean-Charles, A., Ouamrane, K., Tabouillot, A., Chaoui-Boudghane, Y., & Merle, H. (2025) · Ophthalmology Retina · doi:10.1016/j.oret.2025.02.030 · Cited by 1
Choi, J., Kim, K., Lee, J., & Yu, S. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.08.007 · Cited by 1
Lin, C.-C., Tsao, Y.-N., Lin, W.-Y., Ruamviboonsuk, P., Wu, T., Chen, S., & Tsai, C.-L. (2025) · Translational Vision Science & Technology · doi:10.1167/tvst.14.10.15 · Cited by 1
Self-citationLee, Y., Rahman, S., Tao, B. K.-L., Fang, T., Akıl, H., Ferrara, D., Lam, S., & Navajas, E. V. (2025) · International Journal of Retina and Vitreous · doi:10.1186/s40942-025-00744-8 · Cited by 1
“…EVEREST trial demonstrated that while adjunctive PDT produces superior polyp regression (with polyp closure rates ∼ 77–78% when PDT is used, versus ∼ 29% with ranibizumab alone), the 6-month visual gains were comparable among eyes treated with anti-VEGF monotherapy versus combination therapy [16].”
Kikushima, W., Gilead, N., Sherif, M., Zhang, C., Jiang, Z., Sun, C., Ong, C., Hong, C. H., Teo, K. Y. C., Chakravarthy, U., et al. (2026) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2026.02.011 · Cited by 3
Cheng, S., Han, R., Zhang, W., Meng, L., Gu, X., Zhao, X., & Chen, Y. (2026) · British Journal of Ophthalmology · doi:10.1136/bjo-2025-328228 · Cited by 1
Sherif, M., Teo, K. Y. C., Lai, T. Y. Y., Chan, H. H., Fenner, B. J., Lee, W. K., & Cheung, C. M. G. (2026) · Ophthalmology and Therapy · doi:10.1007/s40123-026-01405-1 · Cited by 1
“Indocyanine green angiography (ICGA) is considered the gold standard for confirming the diagnosis of PCV [10, 11]; however, its invasive nature, cost, and limited availability have driven the development of non-invasive diagnostic alternatives.”
Self-citationPark, Y. G., Kang, S., & Roh, Y. (2015) · Europe PMC (PubMed Central) · doi:10.3980/j.issn.2222-3959.2015.02.18 · Cited by 1
Temporally Coherent Illumination Normalization for Indocyanine Green Video Angiography
Lin, W.-Y., Chou, S.-F., Tsai, C.-L., & Chen, S. (2017) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2017.2652446 · Cited by 1
“In Section III, we introduce the EVEREST dataset [2], which provides ICG video angiograms of 60 patients from five asian countries.”
BackgroundMethodInfluentialSelf-citationIntravitreal aflibercept: its role in treatment of neovascular age-related macular degeneration
Cundy, O., Shah, M., & Downes, S. M. (2018) · Expert Review of Ophthalmology · doi:10.1080/17469899.2018.1468250 · Cited by 1
“This irreversible photoreceptor damage eventually leads to central visual loss [17] (Supplementary Figure 4). nAMD can present in one of the three forms: choroidal neovascularization (CNV), retinal angiomatous proliferation (RAP), and idiopathic polypoidal choroidal vasculopathy (IPCV) [18].”
BackgroundInfluentialModern aspects of polypoidal choroidal vasculopathy diagnosis and treatment
Sokolov, K., & Smirnov, A. K. (2019) · Ophthalmology Reports · doi:10.17816/ov16034 · Cited by 1
Verteporfin Photodynamic Therapy for the Treatment of Choroidal Conditions—An Overview
Avaylon, J., & Gallemore, R. P. (2019) · touchREVIEWS in Ophthalmology · doi:10.17925/usor.2019.12.2.69 · Cited by 2
A Case of Polypoidal Choroidal Vasculopathy Associated With Optic Disc Drusen
Sarojini, K., Ling, K. P., Teh, W. M., Haslina, M. A., & Zunaina, E. (2020) · Cureus · doi:10.7759/cureus.10297 · Cited by 1
The Past and Present of Photodynamic Therapy in Ophthalmology
Honda, S. (2021) · Nippon Laser Igakkaishi · doi:10.2530/jslsm.jslsm-42_0016 · Cited by 1
Mishra, S. B., Singh, S. R., Goyal, P., Chakurkar, R., Govindhari, V., Goud, A., & Chhablani, J. K. (2021) · Saudi Journal of Ophthalmology · doi:10.4103/1319-4534.337857 · Cited by 1
Okonkwo, O. N., Akanbi, T., Odubela, T., & Udoh, M.-M. (2023) · Annals of African Medicine · doi:10.4103/aam.aam_68_22 · Cited by 1
“[8,9] The same study found that combination therapy was superior to ranibizumab monotherapy.”
Yuan, P. H., Khan, H. M., Sumita, F. A. G., Monteiro, M. L. R., Preti, R. C., & Navajas, E. V. (2023) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2023.10.009 · Cited by 1
Kim, J., Park, M. S., Cho, B., & Kwon, S. (2024) · Ophthalmology and Therapy · doi:10.1007/s40123-024-01022-w · Cited by 1
“The diagnosis of PCV was based on the presence of branching choroidal vascular networks and polypoidal lesions upon indocyanine green angiography, in accordance with the EVEREST study group criteria [21].”
MethodAdriono, G., Triyoga, I. F., Kadharusman, M. M., Victor, A. A., Djatikusumo, A., Yudantha, A. R., & Hutapea, M. M. (2025) · Clinical ophthalmology · doi:10.2147/opth.s517296 · Cited by 1
Quiroz-Reyes, M. A., Quiroz-Gonzalez, E. A., Quiroz-Gonzalez, M. A., & Lima-Gómez, V. (2025) · BMC Ophthalmology · doi:10.1186/s12886-025-04249-8 · Cited by 1
“The long-term benefits of combination therapy were further supported by Koh et al. (2012) [10], who demonstrated significant and sustained improvements in BCVA with early combination therapy compared with ranibi-zumab monotherapy.”
InfluentialYasukawa, T. (2013) · Expert Review of Ophthalmology · doi:10.1586/17469899.2013.814960 · Cited by 1
Polypoidal Choroidal Vasculopathy
Siringo, F. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-20460-4_78 · Cited by 1
Polypoidal Choroidal Vasculopathy
Maruko, I., & Iida, T. (2016) · Springer eBooks · doi:10.1007/978-81-322-3610-8_16 · Cited by 1
How lack of information hampers decision making in ophthalmology
Salmon, H. A., Chalk, D., & Stein, K. (2017) · British Journal of Healthcare Management · doi:10.12968/bjhc.2017.23.1.28 · Cited by 1
Polypoidal choroidal vasculopathy
Абдулаева, Э. А. (2017) · Kazan medical journal · doi:10.17750/kmj2017-403 · Cited by 2
OCT vs. Indocyanine Green Angiography Features of Polypoidal Choroidal Vasculopathy
Chaikitmongkol, V., Upaphong, P., Patikulsila, D., & Bressler, N. M. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2017.06.006 · Cited by 1
Li, J., Sun, J., Li, B., & Liu, Z. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5565 · Cited by 2
“In the Everest study, IVR injection and PDT in the combination treatment were performed on the same day (12).”
InfluentialGestresster Landarzt mit akuter Visusminderung: Diagnose eindeutig?
Heinrich, D., ULBIG, M. W., Feucht, N., & Maier, M. M. (2017) · Der Ophthalmologe · doi:10.1007/s00347-017-0635-3 · Cited by 1
Zhang, Y., Li, X., Chen, X., Cai, Z., Zhang, Z., Tang, Y., Chang, T., Chen, M., & Zhang, M. (2018) · Medicine · doi:10.1097/md.0000000000013775 · Cited by 1
“However, the deficiency of anti-VEGF monotherapy is the regression of polyps, which was confirmed by the EVEREST study.([15]) The reason for different responsivity could be different balances of VEGF agents and angiogenic epithelium-derived growth factor levels.”
BackgroundWeng, H.-Y., Huang, T., Chang, P.-Y., Ho, W., Hsu, Y.-R., Chen, F., Chen, Y., & Wang, J.-K. (2021) · Applied Sciences · doi:10.3390/app11031194 · Cited by 1
“PDT is effective in occlusion of the polypoidal vascular lesions, and the complete polyp regression rate of PDT alone is greater than that of anti-VEGF monotherapy [11].”
BackgroundSangroongruangsri, S., Chaikledkaew, U., Hanusaha, P., Ratanapakorn, T., & Ruamviboonsuk, P. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s340570 · Cited by 1
Self-citationSun, Z., Gong, Y., Yang, Y., Huang, Y., Yu, S., Pei, J., Lin, B., Zhou, R., Li, Y., Li, Y., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.791935 · Cited by 1
Tan, C. S., Ngo, W. K., Cheong, K. X., & Lim, T. H. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305318 · Cited by 1
Self-citationHikichi, T. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-304688 · Cited by 1
Tan, C. S., Ngo, W. K., & Lim, L. W. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13467 · Cited by 1
Morimoto, M., Matsumoto, H., Mimura, K., & Akiyama, H. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3785-8 · Cited by 1
“However, most prior studies evaluating treatment efficacy for PCV did not distinguish among the PCV subtypes [3, 4].”
ResultOptical coherence tomography angiography in pachychoroid spectrum diseases
Demirel, S., Yanık, Ö., Batıoğlu, F., & Özmert, E. (2018) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-018-4019-4 · Cited by 1
Metadata
- Authors
- Koh, A., Lee, W. K., Chen, L.-J., Chen, S.-J., Hashad, Y., Kim, H., Lai, T. Y., Pilz, S., Ruamviboonsuk, P., Tokaji, E., Weisberger, A., & Lim, T. H.
- Affiliations
- Eye & Retina Surgeons (SG)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Mackay Memorial Hospital (TW)
- Taipei Veterans General Hospital (TW)
- National Yang Ming University (TW)
- Corresponding author
- Koh, Adrian
- Hashad, Yehia
- Weisberger, Annemarie
- ORCID
- Venue
- Retina
- Published
- 2012-09
- Volume
- 32
- Issue
- 8
- Pages
- 1453-1464
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1976433015
- Cited by
- 587
- References
- 30
- Citations by year
- 2026: 21 · 2025: 39 · 2024: 32 · 2023: 20 · 2022: 31 · 2021: 54 · 2020: 46 · 2019: 40 · 2018: 50 · 2017: 63 · 2016: 52 · 2015: 51 · 2014: 39 · 2013: 41 · 2012: 8
- FWCI
- 41.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Retina (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Photodynamic Therapy Research Studies
- Keywords
- verteporfin photodynamic therapy, ranibizumab, combination therapy, polyp regression, best-corrected visual acuity, anti-VEGF therapy, EVEREST trial
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Choroid, Combined Modality Therapy, Double-Blind Method, Coloring Agents, Female, Fluorescein Angiography, Humans, Indocyanine Green, Male, Middle Aged, Photochemotherapy, Polyps, Porphyrins, Visual Acuity, Choroid Diseases, Treatment Outcome, Photosensitizing Agents, Angiogenesis Inhibitors, Intravitreal Injections, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.